Retaining MKP1 expression and attenuating JNK-mediated apoptosis by RIP1 for cisplatin resistance through miR-940 inhibition

Oncotarget

Volumn 5, Issue 5, 2014, Pages 1304-1314

  Wang, Qiong ^a,c   Shi, Shaoqing ^a,c   He, Weiyang ^b   Padilla, Mabel T ^c   Zhang, Lin ^a   Wang, Xia ^a   Zhang, Bin ^b   Lin, Yong ^c  

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^b CHONGQING MEDICAL UNIVERSITY   (China)

^c LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

Author keywords

Apoptosis; Chemoresistance; Cisplatin; JNK; Lung cancer; MKP1; RIP1

Indexed keywords

CELL PROTEIN; CISPLATIN; MICRORNA; MICRORNA 940; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; PHOSPHATASE; PROTEIN MKP1; RECEPTOR INTERACTING PROTEIN 1; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; AGFG1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; DUSP1 PROTEIN, HUMAN; MAP2K4 PROTEIN, HUMAN; MESSENGER RNA; MIRN940 MICRORNA, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; NUCLEOPORIN; RNA BINDING PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL SURVIVAL; CHEMOSENSITIZATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME SYNTHESIS; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN RNA BINDING; PROTEIN STABILITY; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; DUAL SPECIFICITY PHOSPHATASE 1; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MAP KINASE KINASE 4; MICRORNAS; NUCLEAR PORE COMPLEX PROTEINS; RNA, MESSENGER; RNA-BINDING PROTEINS; SIGNAL TRANSDUCTION;

EID: 84898648669     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1798     Document Type: Article

References (46)

1. Maione P, Rossi A, Sacco PC, Bareschino MA, Schettino C and Gridelli C. Advances in chemotherapy in advanced nonsmall-cell lung cancer. Expert opinion on pharmacotherapy. 2010; 11(18):2997-3007.
2. Ulahannan SV and Brahmer JR. Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer. Cancer investigation. 2011; 29(4):325-337.
3. Chang A. Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung cancer (Amsterdam, Netherlands). 2011; 71(1):3-10.
4. Hanahan D and Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-674.
5. Lin Y, Bai L, Chen W and Xu S. The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy. Expert opinion on therapeutic targets. 2010; 14(1):45-55.
6. Boulikas T and Vougiouka M. Cisplatin and platinum drugs at the molecular level. (Review). Oncology reports. 2003; 10(6):1663-1682.
7. Stordal B, Pavlakis N and Davey R. A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship. Cancer treatment reviews. 2007; 33(8):688-703.
8. Sanchez-Perez I, Murguia JR and Perona R. Cisplatin induces a persistent activation of JNK that is related to cell death. Oncogene. 1998; 16(4):533-540.
9. Lin A and Dibling B. The true face of JNK activation in apoptosis. Aging Cell. 2002; 1(2):112-116. 10. Knauf JA and Fagin JA. Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets. Current opinion in cell biology. 2009; 21(2):296-303.
10. Knauf JA and Fagin JA. Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets. Current opinion in cell biology. 2009; 21(2):296-303.
11. Wagner EF and Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nature reviews Cancer. 2009; 9(8):537-549.
12. Haagenson KK and Wu GS. Mitogen activated protein kinase phosphatases and cancer. Cancer biology & therapy. 2010; 9(5):337-340.
13. Haagenson KK and Wu GS. The role of MAP kinases and MAP kinase phosphatase-1 in resistance to breast cancer treatment. Cancer metastasis reviews. 2010; 29(1):143-149.
14. Wang Z, Xu J, Zhou JY, Liu Y and Wu GS. Mitogenactivated protein kinase phosphatase-1 is required for cisplatin resistance. Cancer research. 2006; 66(17):8870-8877.
15. Festjens N, Vanden Berghe T, Cornelis S and Vandenabeele P. RIP1, a kinase on the crossroads of a cell's decision to live or die. Cell death and differentiation. 2007; 14(3):400-410.
16. Lin Y, Devin A, Cook A, Keane MM, Kelliher M, Lipkowitz S and Liu ZG. The death domain kinase RIP is essential for TRAIL (Apo2L)-induced activation of IkappaB kinase and c-Jun N-terminal kinase. Molecular and cellular biology. 2000; 20(18):6638-6645.
17. Kaiser WJ and Offermann MK. Apoptosis induced by the toll-like receptor adaptor TRIF is dependent on its receptor interacting protein homotypic interaction motif. J Immunol. 2005; 174(8):4942-4952.
18. Hur GM, Lewis J, Yang Q, Lin Y, Nakano H, Nedospasov S and Liu ZG. The death domain kinase RIP has an essential role in DNA damage-induced NF-kappa B activation. Genes & development. 2003; 17(7):873-882.
19. Park J, Kanayama A, Yamamoto K and Miyamoto Y. ARD1 binding to RIP1 mediates doxorubicin-induced NFkappaB activation. Biochemical and biophysical research communications. 2012; 422(2):291-297.
20. Wang L, Du F and Wang X. TNF-alpha induces two distinct caspase-8 activation pathways. Cell. 2008; 133(4):693-703.
21. Holler N, Zaru R, Micheau O, Thome M, Attinger A, Valitutti S, Bodmer JL, Schneider P, Seed B and Tschopp J. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nature immunology. 2000; 1(6):489-495.
22. Lin Y, Choksi S, Shen HM, Yang QF, Hur GM, Kim YS, Tran JH, Nedospasov SA and Liu ZG. Tumor necrosis factor-induced nonapoptotic cell death requires receptorinteracting protein-mediated cellular reactive oxygen species accumulation. The Journal of biological chemistry. 2004; 279(11):10822-10828.
23. Tenev T, Bianchi K, Darding M, Broemer M, Langlais C, Wallberg F, Zachariou A, Lopez J, MacFarlane M, Cain K and Meier P. The Ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs. Molecular cell. 2011; 43(3):432-448.
24. Park S, Hatanpaa KJ, Xie Y, Mickey BE, Madden CJ, Raisanen JM, Ramnarain DB, Xiao G, Saha D, Boothman DA, Zhao D, Bachoo RM, Pieper RO and Habib AA. The receptor interacting protein 1 inhibits p53 induction through NF-kappaB activation and confers a worse prognosis in glioblastoma. Cancer research. 2009; 69(7):2809-2816.
25. Wang Q, Chen W, Xu X, Li B, He W, Padilla MT, Jang JH, Nyunoya T, Amin S, Wang X and Lin Y. RIP1 potentiates BPDE-induced transformation in human bronchial epithelial cells through catalase-mediated suppression of excessive reactive oxygen species. Carcinogenesis. 2013; 34(9):2119-2128.
26. Lin Y, Yang Q, Wang X and Liu ZG. The essential role of the death domain kinase receptor-interacting protein in insulin growth factor-I-induced c-Jun N-terminal kinase activation. The Journal of biological chemistry. 2006; 281(33):23525-23532.
27. Devin A, Lin Y and Liu ZG. The role of the death-domain kinase RIP in tumour-necrosis-factor-induced activation of mitogen-activated protein kinases. EMBO reports. 2003; 4(6):623-627.
28. Bai L, Xu X, Wang Q, Xu S, Ju W, Wang X, Chen W, He W, Tang H and Lin Y. A superoxide-mediated mitogenactivated protein kinase phosphatase-1 degradation and c-Jun NH(2)-terminal kinase activation pathway for luteolin-induced lung cancer cytotoxicity. Molecular pharmacology. 2012; 81(4):549-555.
29. Ameres SL and Zamore PD. Diversifying microRNA sequence and function. Nature reviews Molecular cell biology. 2013; 14(8):475-488.
30. Loder S, Fakler M, Schoeneberger H, Cristofanon S, Leibacher J, Vanlangenakker N, Bertrand MJ, Vandenabeele P, Jeremias I, Debatin KM and Fulda S. RIP1 is required for IAP inhibitor-mediated sensitization of childhood acute leukemia cells to chemotherapy-induced apoptosis. Leukemia. 2012; 26(5):1020-1029.
31. Basit F, Humphreys R and Fulda S. RIP1 protein-dependent assembly of a cytosolic cell death complex is required for inhibitor of apoptosis (IAP) inhibitor-mediated sensitization to lexatumumab-induced apoptosis. The Journal of biological chemistry. 2012; 287(46):38767-38777.
32. He W, Wang Q, Srinivasan B, Xu J, Padilla MT, Li Z, Wang X, Liu Y, Gou X, Shen HM, Xing C and Lin Y. A JNK-mediated autophagy pathway that triggers c-IAP degradation and necroptosis for anticancer chemotherapy. Oncogene. 2013, Jul 8. doi: 10.1038/onc.2013.256. [Epub ahead of print].
33. Janssens S, Tinel A, Lippens S and Tschopp J. PIDD mediates NF-kappaB activation in response to DNA damage. Cell. 2005; 123(6):1079-1092
34. Wang X, Ju W, Renouard J, Aden J, Belinsky SA and Lin Y. 17-allylamino-17-demethoxygeldanamycin synergistically potentiates tumor necrosis factor-induced lung cancer cell death by blocking the nuclear factor-kappaB pathway. Cancer research. 2006; 66(2):1089-1095.
35. Bai L, Chen W, Chen W, Wang X, Tang H and Lin Y. IKKbeta-mediated nuclear factor-kappaB activation attenuates smac mimetic-induced apoptosis in cancer cells. Molecular cancer therapeutics. 2009; 8(6):1636-1645.
36. He W, Wang Q, Xu J, Xu X, Padilla MT, Ren G, Gou X and Lin Y. Attenuation of TNFSF10/TRAIL-induced apoptosis by an autophagic survival pathway involving TRAF2-and RIPK1/RIP1-mediated MAPK8/JNK activation. Autophagy. 2012; 8(12):1811-1821.
37. Wang J, Zhou JY, Zhang L and Wu GS. Involvement of MKP-1 and Bcl-2 in acquired cisplatin resistance in ovarian cancer cells. Cell cycle (Georgetown, Tex. 2009; 8(19):3191-3198.
38. Chen CC, Hardy DB and Mendelson CR. Progesterone receptor inhibits proliferation of human breast cancer cells via induction of MAPK phosphatase 1 (MKP-1/DUSP1). The Journal of biological chemistry. 2011; 286(50):43091-43102.
39. Liu R, Zheng HQ, Zhou Z, Dong JT and Chen C. KLF5 promotes breast cell survival partially through fibroblast growth factor-binding protein 1-pERK-mediated dual specificity MKP-1 protein phosphorylation and stabilization. The Journal of biological chemistry. 2009; 284(25):16791-16798.
40. Wang Q, Chen W, Bai L, Chen W, Padilla MT, Lin AS, Shi S, Wang X and Lin Y. Receptor-interacting protein 1 increases chemoresistance by maintaining inhibitor of apoptosis protein levels and reducing reactive oxygen species through a microRNA-146a-mediated catalase pathway. The Journal of biological chemistry. 2014; 289(9):5654-5663.
41. Chen W, Chen W, Wang Q, Bai L, Wang X, Tellez CS, Leng S, Padilla MT, Nyunoya T, Belinsky SA and Lin Y. RIP1 maintains DNA integrity and cell proliferation by regulating PGC-1a-mediated mitochondrial oxidative phosphorylation and glycolysis. Cell Death Different. 2014, 2014 Feb 28. doi: 10.1038/cdd.2014.25. [Epub ahead of print].
42. Tamura Y, Chiba Y, Tanioka T, Shimizu N, Shinozaki S, Yamada M, Kaneki K, Mori S, Araki A, Ito H and Kaneki M. NO donor induces Nec-1-inhibitable, but RIP1-independent, necrotic cell death in pancreatic beta-cells. FEBS letters. 2011; 585(19):3058-3064.
43. Zhang DW, Zheng M, Zhao J, Li YY, Huang Z, Li Z and Han J. Multiple death pathways in TNF-treated fibroblasts: RIP3-and RIP1-dependent and independent routes. Cell research. 2011; 21(2):368-371.
44. Han J, Zhong CQ and Zhang DW. Programmed necrosis: backup to and competitor with apoptosis in the immune system. Nature immunology. 2011; 12(12):1143-1149.
45. Wang X, Chen W and Lin Y. Sensitization of TNF-induced cytotoxicity in lung cancer cells by concurrent suppression of the NF-kappaB and Akt pathways. Biochemical and biophysical research communications. 2007; 355(3):807-812.
46. Ju W, Wang X, Shi H, Chen W, Belinsky SA and Lin Y. A critical role of luteolin-induced reactive oxygen species in blockage of tumor necrosis factor-activated nuclear factorkappaB pathway and sensitization of apoptosis in lung cancer cells. Molecular pharmacology. 2007; 71(5):1381-1388.